Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


Click here to select your areas of interest

Areas of interest

Select to filter on program types

Congresnieuws 22/04/2014

Prevention in AF

Dr. Tommaso Sanna (Rome, Italy) shares an overview on the several tools for AF detection after a stroke event. He focuses on the benefits and limitations of the different tools. Dr. Tze-Fan Chao (Taipei, Taiwan) explains how to treat a patient who needs anticoagulants, but who also experiences a intracranial bleeding event previously, using previous results from an ongoing study. Dr. Jeff Healey (Hamilton, Canada) talks about the debate on stroke and bleeding risk scores. Are these tools in everyday clinical practice or not?

Congresnieuws 22/04/2014

Stroke Prevention and Anticoagulation

The first program of these series presented to you from Cardiostim EHRA Europace 2014 provides an update on stroke prevention and anticoagulation. Prof. dr. Gerhard Hindricks (Leipzig, Germany) provides an update on the current approach when stopping anticoagulation in AF patients might be an option. Prof. dr. Hein J. Heidbüchel (Leuven, Belgium) explains the use of anticoagulation in AF according to the practical guide, which is presented as an addition to the European anticoagulation guidelines. Dr. Robert P. Giugliano (Boston, MA, USA) deals with the results of the ENGAGE AF- TIMI 48 trial. He presents five updated results of subgroup analysis.

Congresnieuws 22/04/2014

Trials and AF

This second program from the Cardiostim EHRA Europace 2014 discusses three trials regarding Atrial Fibrillation Prof. dr. Jonathan Halperin (New York, USA) shares the results of the IMPACT trial, which is a multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices. Dr. Michael Orlov (Boston, USA) talkes about the RATE registry trial. The RATE registry is a multicenter observational study of patients with devices followed between 2007 and 2012 in order to evaluate the clinical implications of device detected AT/AF. Dr. Atul Verma (Newmarket, Canada) presents the results of the DISCERN AF trial, looking at the effect of ablation on Asymptomatic Atrial Fibrillation.

Congresnieuws 22/04/2014

AF in the elderly

Dr. Hugh Calkins (Baltimore, USA) held a state-of-the-art lecture on the knowledge gaps in AF treatment in 80 vs. 60 year-olds. Dr. Yong-Mei Cha (Rochester, MN, USA) presented an example of treatment decisions in a 83 yr-old frail female patient with several comorbidities. Dr. Komandoor Srivathsan (Scottsdale, PH, USA) similarly discussed treatment of AF in a very active 85 year-old surgeon.

Congresnieuws 22/04/2014

AF and Stroke

Prof. dr. Jean-Yves Le Heuzey elaborates on the evolving landscape for treatment of Atrial Fibrillation in Europe, taking the direct oral anticoagulants into account. Prof. dr. Vincent Thijs (Leuven, Belgium) discusses the relation between stroke and atrial fibrillation in the light of anticoagulation with NOACs. Prof. dr. A. John Camm (London, UK) talks about the association of AF and Stroke. In his talk het emphasizes the use of the new CHADS-VASc score for stroke risk estimation.

Congresnieuws 22/04/2014

NOACs / DOACs

Dr. Juan Tamargo (Madrid, Spain) elaborates on the dosing of NOACs in the Elderly. He addresses every-day practice issues such as renal insufficiency, drug-drug Interactions. Dr. Jonathan Piccini (Durham, USA) provides an overview on the role of the newer oral anticoagulants in cardiac procedures such as cardioversion, ablation, stents, and prosthetic valves. Dr. Jan Beyer-Westendorf (Dresden, Germany) shows real-life data from the Dresden NOAC Registry showing non-trial results of NOAC use in the population.

Congresnieuws 22/04/2014

Management in AF

Dr. Tatjana Potpara (Belgrade, Serbia) explains the management considerations in patients with a recent stroke or with a recurrent stroke. Dr. Douglas Packer (Rochester, USA) talks about the CABANA trial. This trial, which is still including patients aims to look beyond AF recurrence. Its comparing the impact of ablation vs drug therapy on mortality, stroke, hospitalization, quality of life and cost of care. Dr. Torben B. Larsen, (Aalborg, Denmark) explores on the management of difficult patients such as the elderly who are for instance cognitively impaired or falling.

Congresnieuws 22/04/2014

Brugada and long QT Syndrome

Dr. Charles Antzelevitch (Utica, USA) explains the genetic and cellular mechanisms of Brugada Syndrome. Dr. Pieter Postema (Amsterdam, NL) introduces websites that cover drugs that may be hazardous to patients with long QT syndrome or Brugada Syndrome. Dr. Hanno Tan (Amsterdam, NL) talks about drug-induced Brugada syndrome, and how high or low these risks are.

Congresnieuws 22/04/2014

Treatment considerations

Dr. Maddalena Lettino (Rome, IT) discusses the treatment options of anticoagulation prior to and after Cardioversion. Prof.dr. Harry J. Crijns (Maastricht, NL) explores on the importance of treatment in AF subgroups: Rate or Rhythm Control in Heart Failure.

Congresnieuws 22/04/2014

Drugs and Cardiac disease

Dr. Paul Dorian (Toronto, Canada) explaines the concomitant use of Antiplatelet drugs and Anticoagulants drugs and what are the most important issues to address. Prof. dr. Christian Sticherling (Basel, Switserland) talks about the management problems in patients who are taking oral anticoagulation and need Ablation or Device Implantation as well. Dr. Isabelle van Gelder (Groningen, The Netherlands) elaborates on the question whether rhythm control with antiarrhythmic drugs or catheter ablation will reduce the risk of stroke?

Congresnieuws 22/03/2014

ACC 2014 Pulmonary Embolism

This series of interviews focuses on Pulmonary Embolism. Jeffrey I. Weitz (Hamilton, Canada) provides an overview on the use of the new oral anticoagulants in the treatment of embolic disease. David Jiménez (Madrid, Spain) explains the Wait and Watch approach in the treatment of submassive PE. Gregory Piazza (Boston, MA, USA) focuses on Chronic thromboembolic pulmonary hypertension and the link with pulmonary embolism.

Congresnieuws 22/03/2014

ACC 2014 Clinical Studies

In this program from the ACC in Washington some clinical studies will be discussed. Stefan Verheye (Antwerp, Belgium) describes the COSIRA Trial, which deals with the Coronary Sinus Reducer for Treatment of Refractory Angina. David T. Martin (Burlington, MA, USA) tells the results of his randomized trial of Anticoagulation Guided by Remote Rhythm Monitoring in Patients with Implanted Cardioverter-Defibrillator and Resynchronization Devices. Carlo Briguori (Napels, Italy) explains the results from the NAPLES III trial. The aim of this trila was to prevent or limit events during Coronary Stenting.